BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23857601)

  • 1. IL-17A stimulates the progression of giant cell tumors of bone.
    Xu M; Song ZG; Xu CX; Rong GH; Fan KX; Chen JY; Zhang W; Jia JP; Han G; Wang W; Chai W; Liang WT; Bi WZ; Wang Y
    Clin Cancer Res; 2013 Sep; 19(17):4697-705. PubMed ID: 23857601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone.
    Balla P; Moskovszky L; Sapi Z; Forsyth R; Knowles H; Athanasou NA; Szendroi M; Kopper L; Rajnai H; Pinter F; Petak I; Benassi MS; Picci P; Conti A; Krenacs T
    Histopathology; 2011 Sep; 59(3):376-89. PubMed ID: 22034878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
    Han YX; Liang DY
    Int J Oncol; 2012 Mar; 40(3):673-8. PubMed ID: 22076387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-125a Promotes the Progression of Giant Cell Tumors of Bone by Stimulating IL-17A and β-Catenin Expression.
    Jin H; Li DW; Wang SN; Luo S; Li Q; Huang P; Wang JM; Xu M; Xu CX
    Mol Ther Nucleic Acids; 2018 Dec; 13():493-502. PubMed ID: 30388623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
    Matsubayashi S; Nakashima M; Kumagai K; Egashira M; Naruke Y; Kondo H; Hayashi T; Shindo H
    Pathol Res Pract; 2009; 205(9):626-33. PubMed ID: 19324500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
    Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.
    Balla P; Maros ME; Barna G; Antal I; Papp G; Sapi Z; Athanasou NA; Benassi MS; Picci P; Krenacs T
    PLoS One; 2015; 10(5):e0125316. PubMed ID: 25933380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone.
    Roux S; Quinn J; Pichaud F; Orcel P; Chastre E; Jullienne A; De Vernejoul MC
    J Cell Physiol; 1996 Sep; 168(3):489-98. PubMed ID: 8816903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone-related protein (PTHrP) modulates adhesion, migration and invasion in bone tumor cells.
    Mak IW; Turcotte RE; Ghert M
    Bone; 2013 Jul; 55(1):198-207. PubMed ID: 23466453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
    Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
    Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.
    Kim G; Khanal P; Lim SC; Yun HJ; Ahn SG; Ki SH; Choi HS
    Carcinogenesis; 2013 Feb; 34(2):341-50. PubMed ID: 23125217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of giant cell tumour of bone cells for Noonan syndrome/cherubism-related mutations.
    Moskovszky L; Idowu B; Taylor R; Mertens F; Athanasou N; Flanagan A
    J Oral Pathol Med; 2013 Jan; 42(1):95-8. PubMed ID: 22725657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.
    Atkins GJ; Haynes DR; Graves SE; Evdokiou A; Hay S; Bouralexis S; Findlay DM
    J Bone Miner Res; 2000 Apr; 15(4):640-9. PubMed ID: 10780856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
    Cowan RW; Singh G; Ghert M
    J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Matrix Metalloproteinase-9 and CD34 in Giant Cell Tumor of Bone.
    Zhou X; Liu XZ; Fan GT; Wu SJ; Zhao JN; Shi X
    Orthop Surg; 2016 May; 8(2):220-5. PubMed ID: 27384731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H; Ishihara S; Toda Y; Oda Y
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal Cell-Derived CCL20 Promotes Tumor Progression and Osteolysis in Giant Cell Tumor of Bone.
    Zhao C; Wang D; Tang L; Zhang Z; Li S; Qian M; Wu Z; Zhou W; Liu M; Luo J; Liu T; Li Z; Xiao J
    Cell Physiol Biochem; 2018; 51(5):2472-2483. PubMed ID: 30537747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone.
    Mosakhani N; Pazzaglia L; Benassi MS; Borze I; Quattrini I; Picci P; Knuutila S
    Histol Histopathol; 2013 May; 28(5):671-8. PubMed ID: 23172052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.